The University of British Columbia

Provincial Health Services Authority

Helen Merkens

Calvin D Roskelley

Kelly Marshall McNagny

David Huntsman

Aruna Somasiri

François Bénard

Zhengxing Zhang

Hsiou-Ting Kuo

Kelly M Mcnagny

This application relates to compounds of Formula I. R, Rand Ris —COH, —SOH, —SOH, —SOH, —POH, —POH or —POH. Ris a linker, e.g. butylene. Ris a linkage, e.g. —O—, —S—, —S(O)—, S(O)—, —NHC(O)—, —C(O)NH—, or 1,2,3-triazole. R4 is —(CH)CH(R)(CH)— wherein Ris —(CH)CHor certain aromatic fused-ring systems. Rand Rare hydrogen or methyl. Each Xaa(if present) is an amino acid. Ris a radiolabeling group, e.g.: a radiometal chelator optionally bound by a radiometal; an aryl substituted with a radioisotope; a prosthetic group containing a trifluoroborate; or a prosthetic group containing a silicon-fluorine-acceptor moiety. The compounds may be useful for imaging prostate-specific membrane antigen (PSMA)-expressing tissues or for treating PSMA-expressing diseases (e.g. cancer).

Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer

Methods and kits for detecting cancer and monitoring cancer progression are described. The method involves analyzing a sample containing nucleic acids or proteins from a patient for decreased expression of endoglycan and/or increased expression of podocalyxin.

Methods for detecting and treating cancer

Growing community of inventors

Burnaby, Canada

Helen Merkens